Navigation Links
Palatin Technologies Provides Update Regarding Its Obesity Research/Development Collaboration with AstraZeneca
Date:9/7/2012

CRANBURY, N.J., Sept. 7, 2012 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) today announced that its collaboration partner,  AstraZeneca, has decided to discontinue further development of AZD2820, one of a number of collaboration compounds in various stages of development for the treatment of obesity.  AstraZeneca remains committed to this collaboration program and to the continued advancement of melanocortin agonists for treatment of obesity.

AZD2820, a subcutaneously-administered peptide melanocortin-4 receptor partial agonist, was a clinical candidate under development by AstraZeneca from a collaborative research program with Palatin Technologies. As previously announced, a Phase I trial of AZD2820 was halted following a serious adverse event. The decision to discontinue development of the compound was made based on investigations and review conducted by AstraZeneca that followed this incident. While not confirmed, it could not be excluded that the serious adverse event was linked to AZD2820. The investigation further concluded that it is unlikely that the serious adverse event was related to melanocortin receptor activation as an approach for the treatment of obesity.

"We are pleased that the subject has fully recovered from this adverse event," said Dr. Carl Spana, President and Chief Executive Officer of Palatin. "The AZD2820 compound is part of a broader research and development collaboration with AstraZeneca. We have multiple classes of collaboration compounds in various stages of preclinical testing and AstraZeneca has informed us that they remain committed to the advancement of collaboration compounds for treatment of obesity."

Pursuant to the terms of the research collaboration and license agreement with AstraZeneca, Palatin is eligible for milestone payments upon achieving development and regulatory milestones and further payments on achievement of sales targets, in addition to royalties on sales of app
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Palatin Technologies, Inc. To Report Fiscal Year 2012 Fourth Quarter Results; Teleconference and Webcast to be held on September 11, 2012
2. Palatin Technologies, Inc. Announces Pricing of $35 Million Private Placement of Common Stock and Warrants
3. Palatin Technologies Announces Halting of Phase I Clinical Trial of Obesity Compound in AstraZeneca Research Collaboration
4. Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on May 14, 2012
5. Palatin Technologies, Inc. To Report Fiscal Year 2012 Third Quarter Results; Teleconference and Webcast to be held on May 14, 2012
6. Palatin Technologies, Inc. to Present at the 24th Annual ROTH OC Growth Stock Conference
7. Palatin Technologies to Present at Windhovers Therapeutic Area Partnerships Conference
8. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
9. Palatin Technologies, Inc. to Report Fiscal Year 2012 First Quarter Results; Teleconference and Webcast to be held on November 15, 2011
10. Lifeline Biotechnologies Receives Patent for Methods to Collect and Analyze Breast Thermal Data to Determine Suspect Conditions
11. Life Technologies to Present at UBS Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... March 4, 2015 ... Paris en décembre 2011, l,étude ...   », qui compare   l es ...   sorafénib dans le carcinome hépatocellulaire avancé, a ... du foie avancé   ; les résultats sont ...
(Date:3/3/2015)... 03, 2015 Experts and industry insiders ... one event: the Alltech REBELation exploring innovation, inspiration and ... Now in its 31st year, Alltech’s annual international conference ... and the opportunity to join the REBELation at an ... 11:59 p.m. EST, at which point the standard early ...
(Date:3/3/2015)... -- Adaptive Biotechnologies announced today that Chad Cohen ... Director as Chair of the Audit Committee. ... all finance, treasury and accounting functions. Since joining Zillow ... and accounting functions, and led the finance organization through ... was named Puget Sound Business Journal,s CFO of the ...
(Date:3/3/2015)... Calif. (PRWEB) March 03, 2015 The ... management excellence were honored by the Global Supply ... event which took place on Wednesday, February 25th, 2015, ... The GSCRC was formed to bring together supply chain ... leaders to advance the professional discipline through opportunities to ...
Breaking Biology Technology:Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 2Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 3Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 4Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 5Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 6World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 2World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 3World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 4Adaptive Biotechnologies adds Chad Cohen, Zillow Group CFO, to Board of Directors 2Global Supply Chain Resiliency Council Names Award Winners 2Global Supply Chain Resiliency Council Names Award Winners 3Global Supply Chain Resiliency Council Names Award Winners 4
... Aug. 16, 2011 Quanterix Corporation, a company ... based on its revolutionary Si ngle ... STRATEC Biomedical AG (Frankfurt: SBS; Prime Standard, TecDAX), ... of automated analyzer systems, today announced an agreement ...
... The Society of Interventional Radiology Foundation launched a ... the future of the specialty with its announcement ... student conducting preclinical research in interventional radiology during ... prestigious Medical Research Fellows Program. (Logo: ...
... 2011 PharmAthene, Inc. (NYSE Amex: PIP ... and chemical threats, announced today that the Company has ... of Defense (DoD) Broad Agency Announcement for studies directed ... the bioproduction of its nerve agent medical countermeasure program. ...
Cached Biology Technology:Quanterix and STRATEC Announce Strategic Partnership 2Quanterix and STRATEC Announce Strategic Partnership 3Society of Interventional Radiology Foundation Funds Howard Hughes Medical Institute Award 2Society of Interventional Radiology Foundation Funds Howard Hughes Medical Institute Award 3Department of Defense Awards $5.7 Million Contract to PharmAthene for Nerve Agent Medical Countermeasure Program 2Department of Defense Awards $5.7 Million Contract to PharmAthene for Nerve Agent Medical Countermeasure Program 3Department of Defense Awards $5.7 Million Contract to PharmAthene for Nerve Agent Medical Countermeasure Program 4
(Date:2/5/2015)... 28, 2015 New Market Research ... Segment Forecasts To 2020 has Been Added to GrandViewReseach.com ... is expected to reach USD 5.10 billion by 2020, ... Inc. IR cameras help identify the site of tissue ... witness surging demand in medical imaging applications. They have ...
(Date:1/22/2015)... Markets ( http://www.researchandmarkets.com/research/4trb7t/biometrics_a ) has announced the addition ... report to their offering. , The primary ... is who she/he is claiming to be, and for this ... physical characteristics, such as fingerprint, hand or palm print, iris, ...
(Date:1/22/2015)... MADISON, Wis. , Jan. 15, 2015  BellBrook ... for drug discovery, announced the launch of a ... of the company,s Transcreener UDP Assay, a high ... enzymes. The new assay will allow for sensitive ...
Breaking Biology News(10 mins):IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 3Biometrics - A Global Market Overview 2Biometrics - A Global Market Overview 3BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2
... Novartis announced today that scientists at the Novartis ... from the Genomics Institute of the Novartis Research Foundation ... The Scripps Research Institute have discovered a novel compound ... drug resistant malaria. Major support for the project was ...
... California Institute of Technology (Caltech) have devised a new ... visualize the structure of molecules. The technique, which was ... water coats surfaces at room temperature, can also be ... molecules, including antibodies and other biomolecules. A paper ...
... of the first implantable artificial kidney, in a development ... The device, which would include thousands of microscopic ... metabolic and water-balancing roles of a real kidney, is ... and physicians nationwide, led by Shuvo Roy, PhD, in ...
Cached Biology News:Novartis and collaborators discover novel antimalarial drug candidate 2Novartis and collaborators discover novel antimalarial drug candidate 3Caltech chemists develop simple technique to visualize atomic-scale structures 2Caltech chemists develop simple technique to visualize atomic-scale structures 3UCSF unveils model for implantable artificial kidney to replace dialysis 2UCSF unveils model for implantable artificial kidney to replace dialysis 3